Fingerprint
Dive into the research topics of 'A phase i trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically